

Drug Utilization Review (DUR) Meeting Minutes

April 7th, 2008

Members Present: Patricia Churchill, Cheryl Huber, Norman Byers, Carrie Sorenson, Greg Pfister, Bob Treitline, Kim Krohn, Jeffrey Hostetter, John Savageau, Scott Setzepfandt, Leeann Ness, and Carlotta McCleary.

Medicaid Pharmacy Department: Brendan Joyce, Gary Betting

HID Staff Present: Candace Rieth

Members Absent: Albert Samuelson, Todd Twogood

Chairman, C. Huber, called the meeting to order at 1:03pm. C. Huber asked for a motion to approve the minutes from the February meeting. B. Joyce asked Dr. Byers if Pharma means all pharmaceutical companies (e.g. brand, generic, mixed brand and generic, biologic, etc.) in relation to Pharma contact of board members. Dr. Byers replied yes, that is the definition of Pharma that he meant. The minutes have Pharma misspelled and this will be corrected. P. Churchill moved that the minutes be approved as amended and G. Pfister seconded the motion. Chair, C. Huber, called for a voice vote to approve the minutes, which passed with no audible dissent.

Budget Update

B. Joyce had no new information to present regarding the budget. G. Pfister asked if DUR Board member honorariums could be reviewed at the next meeting. This will be an agenda item for the June meeting.

B. Joyce informed board members that Dr. Samuelson will no longer be able to serve on the DUR Board. Dr. Samuelson has scheduling conflicts that will not allow him to attend the Monday meetings. B. Joyce suggested that board members make recommendations for a physician to fill Dr. Samuelson's vacancy on the board.

Antipsychotic Review

B. Joyce reviewed antipsychotic information with the Board. Along with the low dose issue, the Department would like the Board to review alternative dosage forms of the antipsychotics such as zydys, soltabs, follow along products and injectables with large price differences. At the last board meeting, Dr. Samuelson asked that the Department bring information to the board regarding poly-pharmacy. Brendan reviewed the Comprehensive Neuroscience report with the board. This report showed board members the number of patients on multiple CNS medications, including antipsychotics. Also included in the pack was a draft letter to providers regarding the low dose antipsychotic issue. A motion was made by J. Hostetter to place alternate dosage forms of the antipsychotic medications on prior authorization. J. Savageau seconded the motion. Chair C. Huber called for a voice vote and the motion passed with one audible dissent. Larry Martinez, representing Ortho McNeil Jansen, spoke against prior authorization of Risperdal Consta. R. Treitline made a motion to prior authorize Invega. P. Churchill seconded the motion. Larry Martinez, representing Ortho McNeil Jansen, spoke against prior authorization of Invega. After much discussion, P. Churchill called for a vote. Motion passed with two audible dissents. A recommendation will be made to the legislative council that the DUR Board would prior authorize alternate dosage forms and Invega if given the opportunity to prior authorize the antipsychotic class of medications.

Anticonvulsant Review

The anticonvulsant review is based on the 2007 legislative session requesting information on classes of medications that currently are exempt from prior authorization. B. Joyce reviewed utilization data of the Anticonvulsant meds including a market share report. Jerry Clewell, representing Abbott, spoke against prior authorization of the anticonvulsants and suggested that the Board review the American Academy of Neurology position statement as well as the NICE

guidelines. B. Joyce asked the Board if they would like the ability to review and manage anticonvulsants. Board members suggested bringing more information to the June meeting regarding this topic. Information requested includes a list of which products are going generic in the near future, which providers are prescribing this class of medications, parameters of treatment for anticonvulsants versus mood-stabilizers, and examples of changes that have been made to this class in other states. B. Joyce said that he would gather this information and bring it to the June DUR Board meeting.

Criteria Recommendations

The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and usually are consistent with new indications, new drugs added, new warnings, etc. These proposed criteria will be added to the current set of criteria, and will be used in future DUR cycles. K. Krohn moved to approve the new criteria and G. Pfister seconded the motion. C. Huber called for a voice vote and the motion passed with no audible dissent.

The next DUR board meeting will be June 2nd, 2008. C. Sorenson made a motion to adjourn the meeting and P. Churchill seconded. Chair C. Huber adjourned the meeting at 3:10 pm.